114 related articles for article (PubMed ID: 7754546)
1. Distribution of the carbohydrate antigens, DU-PAN-2 and CA19-9, in tumors of the lung.
Ohshio G; Yamaki K; Imamura T; Suwa H; Chang CY; Wada H; Sueno Y; Imamura M
Tumori; 1995; 81(1):67-73. PubMed ID: 7754546
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical studies on the localization of cancer associated antigens DU-PAN-2 and CA19-9 in carcinomas of the digestive tract.
Ohshio G; Ogawa K; Kudo H; Yamabe H; Nakashima Y; Kim YC; Endo K; Watanabe Y; Manabe T; Tobe T
J Gastroenterol Hepatol; 1990; 5(1):25-31. PubMed ID: 2103381
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical localization of CEA, CA19-9 and DU-PAN-2 in hepatitis C virus-infected liver tissues.
Kitagawa Y; Iwai M; Muramatsu A; Tanaka S; Mori T; Harada Y; Okanoue T; Kashima K
Histopathology; 2002 May; 40(5):472-9. PubMed ID: 12010368
[TBL] [Abstract][Full Text] [Related]
4. Expression of carbohydrate antigens (SSEA-1, sialyl-Lewis X, DU-PAN-2 and CA19-9) and E-selectin in urothelial carcinoma of the renal pelvis, ureter, and urinary bladder.
Kajiwara H; Yasuda M; Kumaki N; Shibayama T; Osamura Y
Tokai J Exp Clin Med; 2005 Sep; 30(3):177-82. PubMed ID: 16285609
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical heterogeneity of type 1 blood group antigen expressions in testicular germ cell tumors.
Kamoshida S; Satoh Y; Yasuda M; Kajiwara H; Tsukinoki K; Osamura RY
Oncol Rep; 2002; 9(4):845-51. PubMed ID: 12066220
[TBL] [Abstract][Full Text] [Related]
6. Serum carbohydrate antigen elevations in endometrial adenocarcinomas: characterization of DU-PAN-2 expression as a tumor marker.
Yasuda M; Saito K; Kobayashi Y; Muramatsu T; Miyamoto T; Murakami M; Shinozuka T; Ishizuka B; Makino T; Kajiwara H; Osamura RY
J Obstet Gynaecol Res; 2004 Feb; 30(1):59-64. PubMed ID: 14718023
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical study of type-1 blood antigen expressions in thyroid tumors: the significance for papillary carcinomas.
Kamoshida S; Ogane N; Yasuda M; Muramatsu T; Bessho T; Kajiwara H; Osamura RY
Mod Pathol; 2000 Jul; 13(7):736-41. PubMed ID: 10912932
[TBL] [Abstract][Full Text] [Related]
8. Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals.
Attanoos RL; Thomas DH; Gibbs AR
Histopathology; 2003 Oct; 43(4):387-92. PubMed ID: 14511258
[TBL] [Abstract][Full Text] [Related]
9. Expression of CA19-9, DU-PAN-2, and SPan-1 antigens on two types of normal salivary mucins.
Ho JJ; Norton K; Chung YS; Kim YS
Oncol Res; 1993; 5(9):347-56. PubMed ID: 7518709
[TBL] [Abstract][Full Text] [Related]
10. Progenitor stem cell marker expression by pulmonary carcinomas.
Moreira AL; Gonen M; Rekhtman N; Downey RJ
Mod Pathol; 2010 Jun; 23(6):889-95. PubMed ID: 20305619
[TBL] [Abstract][Full Text] [Related]
11. Determination of tumor marker levels in cystic fluid of benign liver cysts.
Iwase K; Takenaka H; Oshima S; Yagura A; Nishimura Y; Yoshidome K; Tanaka T
Dig Dis Sci; 1992 Nov; 37(11):1648-54. PubMed ID: 1385056
[TBL] [Abstract][Full Text] [Related]
12. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
[TBL] [Abstract][Full Text] [Related]
13. Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel.
Sosolik RC; McGaughy VR; De Young BR
Mod Pathol; 1997 Jul; 10(7):716-9. PubMed ID: 9237183
[TBL] [Abstract][Full Text] [Related]
14. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients.
Narimatsu H; Iwasaki H; Nakayama F; Ikehara Y; Kudo T; Nishihara S; Sugano K; Okura H; Fujita S; Hirohashi S
Cancer Res; 1998 Feb; 58(3):512-8. PubMed ID: 9458099
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites.
Mitselou A; Batistatou A; Nakanishi Y; Hirohashi S; Vougiouklakis T; Charalabopoulos K
Histol Histopathol; 2010 Oct; 25(10):1257-67. PubMed ID: 20712010
[TBL] [Abstract][Full Text] [Related]
16. DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease.
Mahvi DM; Seigler HF; Meyers WC; Kalthoff H; Schmiegel WH; Metzgar RS
Pancreas; 1988; 3(4):488-93. PubMed ID: 3174610
[TBL] [Abstract][Full Text] [Related]
17. Comparative studies on expression of CA 19-9 and DU-PAN-2 in pancreatic cancer tissue.
Takasaki H; Uchida E; Tempero MA; Burnett DA; Metzgar RS; Pour PM
Int J Pancreatol; 1987; 2(5-6):349-60. PubMed ID: 3320227
[TBL] [Abstract][Full Text] [Related]
18. [Immunohistochemical study on the expression of carbohydrate antigens in normal squamous epithelia and squamous cell carcinomas of the uterine cervix].
Tsukada S
Nihon Sanka Fujinka Gakkai Zasshi; 1994 Feb; 46(2):137-44. PubMed ID: 7907353
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.
Bateman AC; al-Talib RK; Newman T; Williams JH; Herbert A
Histopathology; 1997 Jan; 30(1):49-56. PubMed ID: 9023557
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis.
Carella R; Deleonardi G; D'Errico A; Salerno A; Egarter-Vigl E; Seebacher C; Donazzan G; Grigioni WF
Am J Surg Pathol; 2001 Jan; 25(1):43-50. PubMed ID: 11145250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
